SELLAS Life Sciences Highlights Promising Phase 2 Results
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a forward-thinking clinical biopharmaceutical company dedicated to advancing treatments for various cancer types, has reported significant findings from its Phase 2 trial involving SLS009 combined with azacitidine (AZA) and venetoclax (VEN). These results were shared at a renowned hematology conference, showcasing the potential of SLS009 in treating relapsed or refractory acute myeloid leukemia (AML) with myelodysplastic syndrome-related changes (AML-MR).
Impressive Patient Response Rates
The study demonstrated an overall response rate of 46% across all patient cohorts, with a remarkable 58% in those who had undergone one prior line of therapy. These figures underline the potential efficacy of SLS009 when used in tandem with established therapies like AZA and VEN, particularly in patients with challenging treatment backgrounds.
Survival Outcomes Show Promise
Median overall survival (mOS) figures further emphasize the clinical significance of SLS009's application. In the least-pretreated patient cohort, mOS reached an encouraging 8.9 months—well above historical averages for similar patient profiles. This is a critical finding given that historical benchmarks indicate mOS of only about 2.5 months for patients in similar circumstances. The results suggest a pivotal role for SLS009 in enhancing survival among this patient population.
Combination Therapy Safe and Feasible
The SLS009 regimen, administered at 30 mg intravenously twice weekly alongside AZA/VEN, exhibited an excellent safety profile. Importantly, researchers reported no observed dose-limiting toxicities, reinforcing the feasibility of this combination approach. The tolerability of SLS009, even among heavily pretreated patients, positions it as a promising option for ongoing and future therapies.
Next Steps for Investigation
Following the encouraging results, SELLAS Life Sciences intends to expand its research into combining SLS009 with AZA/VEN for newly diagnosed AML patients, particularly those presenting high-risk features. This strategic move to explore further applications of SLS009 speaks to the compound's versatility and efficacy.
Understanding Patient Populations
This study involved 35 evaluable R/R AML-MR patients, primarily those with adverse-risk factors, including significant genetic mutations such as ASXL1 and TP53. Notably, patients with these mutations showed promising response rates of 48% and 57% respectively. Understanding which genetic profiles best respond to such treatments could dramatically shape future clinical strategies in AML management.
Statements from Leadership
Dr. Dragan Cicic, Senior Vice President and Chief Development Officer of SELLAS, expressed optimism regarding the results, noting that these findings further validate SLS009's potential in overcoming resistance to venetoclax-based therapies. The study's success in engaging treatment-resistant populations is pivotal for future developments in AML therapeutics.
Presentation Insights
SELLAS' findings will be included in a poster presentation titled "Phase 2 Study of SLS009 in Combination with Azacitidine and Venetoclax for Relapsed/Refractory AML with MDS-Related Changes (AML-MR) After Prior Venetoclax Treatment." The presentation aims to delve into the dynamics of this combination therapy, highlighting its role in improving outcomes for patients with a dire need for effective treatment options.
About SELLAS Life Sciences
SELLAS is dedicated to pioneering innovative therapies in oncology, with a focus on addressing niches left open by existing treatments. Their lead product candidate, GPS, aims to treat an extensive range of malignancies targeting the WT1 protein, with the potential to serve both in monotherapy and combination regimens. Additionally, SLS009 appears to offer a differentiated approach in its class of cancer therapeutics, showcasing improved response rates in challenging patient groups.
Frequently Asked Questions
What are the key findings from the Phase 2 study of SLS009?
The Phase 2 study demonstrated a 46% overall response rate and a median overall survival of 8.9 months in the least pretreated cohort.
How safe was SLS009 in the study?
The study reported no dose-limiting toxicities for SLS009 when combined with AZA/VEN, indicating a favorable safety profile.
What are the next steps for SELLAS Life Sciences?
SELLAS plans to expand research to include SLS009’s application in newly diagnosed AML patients with high-risk features.
What mutations were commonly observed in the study participants?
Participants frequently exhibited ASXL1 and TP53 mutations, which significantly impacted response rates.
How does SLS009 compare to existing therapies?
SLS009 has shown promising activity against venetoclax resistance and offers a new therapeutic option for patients with few alternatives.
